Pseudobulbar Palsy: Diagnostic Workup and Management
For pseudobulbar palsy, prioritize early swallow screening before any oral intake, followed by videofluoroscopy if abnormal, and treat pseudobulbar affect with dextromethorphan/quinidine as the FDA-approved first-line agent, with SSRIs as alternatives.
Diagnostic Workup
Swallow Assessment (Critical First Step)
- Screen all patients before initiating oral intake using a simple validated bedside protocol 1
- Screening should be performed by a speech-language pathologist (SLP) or trained nurse/occupational therapist if SLP unavailable 1
- High-risk patients require videofluoroscopy swallowing study (VFSS) regardless of screening results, including those with:
- Brain stem stroke
- Pseudobulbar palsy
- Multiple strokes 1
Comprehensive Swallow Evaluation
If bedside screening is abnormal 1:
- Complete bedside examination by SLP to define swallow physiology
- VFSS/modified barium swallow to identify physiological abnormalities and test treatment strategies
- Fiberoptic endoscopic examination of swallowing (FEES) as alternative to VFSS
- The only predictive signs of aspiration are severe dysphagia and abnormal pharyngeal sensation 1
Neurological Assessment
Look for specific features 2:
- Transfer dysphagia with aspiration risk
- Dysarthria
- Drooling
- Dystonia and spasticity
- Behavioral changes
- Pseudobulbar affect: uncontrollable laughing/crying episodes
Pseudobulbar Affect Screening
- Use validated scales 3:
- Pathological Laughing and Crying Scale
- Center for Neurologic Study-Lability Scale (CNS-LS) - score ≥13 indicates PBA 4
- Assess for mood swings and other mood disorders 3
- Incidence: 10-48% in stroke patients 3
Management
Pseudobulbar Affect Treatment
Pharmacologic therapy 5:
First-line: Dextromethorphan/quinidine
- FDA-approved specifically for PBA 3, 5
- Most evidence-based option for emotional lability causing distress
- Class IIa recommendation, Level A evidence 5
Important caveat for elderly patients 6:
- Use dextromethorphan/quinidine with caution in older adults
- Limited efficacy in dementia patients without PBA
- Increased risk of falls and drug-drug interactions
- Consider carefully in patients ≥75 years
Alternative: SSRIs
- Reasonable therapeutic trial for emotional lability 5, 1
- SSRIs are preferred antidepressant class in stroke patients 1
- Class IIa recommendation, Level A evidence 5
- Generally well-tolerated with favorable side effect profile
Non-Pharmacologic Interventions
- Patient and family education about PBA 3
- Explain that episodes are neurologic, not psychiatric
- Acknowledge condition to defuse uncomfortable situations
- Cognitive and emotional therapy 3
- Psychotherapy and support groups 3
Swallowing Management
Based on VFSS findings 1:
- Modify food consistency in consultation with dietetics
- Implement compensatory strategies identified during diagnostic assessment
- Monitor for aspiration pneumonia risk
- Consider alternative feeding routes if severe
Common Pitfalls
Misdiagnosis as depression: PBA involves involuntary emotional expression disconnected from internal mood state, unlike depression where affect matches mood 7, 8, 9
Underrecognition: Only 12% of patients may be formally diagnosed despite 30% having symptoms 4
Delayed treatment: Patients with undiagnosed PBA are significantly less likely to receive appropriate treatment (12.5% vs 47.4% in diagnosed patients) 4
Assuming all emotional lability needs treatment: Most cases decline over time without intervention; treat only when causing distress or interfering with rehabilitation 1
Drug interactions in elderly: Be vigilant about dextromethorphan/quinidine interactions with other CNS medications, particularly in patients on multiple agents 6
Skipping swallow screening: This increases pneumonia and malnutrition risk - screen before any oral intake 1